NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director
February 20 2025 - 5:00AM
NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”),
a comprehensive fertility services provider in Asia helping couples
and individuals obtain access to fertility treatments, today
announced that the Nasdaq Hearings Panel (the “Panel”) has granted
the Company's request for continued listing on The Nasdaq Stock
Market, subject to specific conditions. Additionally, the Company
announced the appointment of Mr. Thorain Ko as Business Development
Director to drive its expansion initiatives.
Nasdaq Listing UpdateThe Panel has granted
NewGen’s request to continue its listing on the Nasdaq Stock Market
subject to several conditions that must be met within specified
time frames. The Company has already made progress on its
compliance plan, including carrying out a reverse split on February
11, 2025 and achieving compliance with the shareholders' equity
minimum for listing on the Nasdaq Capital Market ahead of schedule
through note conversions. The Company intends to apply for
transition to the Nasdaq Capital Market on or before February 26,
2025.
Appointment of Business Development DirectorIn
a strategic move to strengthen its management team, NewGen has
appointed Mr. Thorain Ko as Business Development Director. Mr. Ko
will spearhead the Company's efforts to develop its recently
announced lifetime egg-freezing business in China and broader Asian
markets, while also driving sales initiatives across the Company's
fertility service offerings.
Mr. Ko brings over 30 years of experience in business
development, healthcare, and direct-selling to NewGen. Most
recently, he served as a Sales and Marketing Director at USANA
Health Sciences, specializing in nutritional supplements, skincare,
and weight management products. Previously, Mr. Ko held leadership
positions at Jeunesse Global Group Ltd. as Marketing Manager and at
HEC International, LLC as Operations Director. Mr. Ko holds a
Bachelor of Laws (LLB) from the University of London and a Master
of Corporate Governance (MCG) from Hong Kong Polytechnic
University.
Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen,
commented, “We are pleased with the Panel's decision to grant our
continued listing request and appreciate their recognition of our
progress in meeting Nasdaq's requirements. As we work to complete
our compliance plan, we are simultaneously strengthening our
management team with the addition of Mr. Ko, whose extensive
experience in healthcare business development across Asia will be
instrumental in driving our growth initiatives, particularly in our
lifetime egg-freezing business. These developments reflect our
commitment to creating value for shareholders while expanding
access to fertility services across Asia.”
About NewGen
NewGen is a comprehensive fertility services provider in Asia
helping couples and individuals obtain access to fertility
treatments. With a mission to aid couples and individuals in
building families regardless of fertility challenges, NewGen has
dedicated itself to creating increased access to infertility
treatment and providing comprehensive fertility services for its
customers. NewGen’s management team collectively has over a decade
of experience in the fertility industry. NewGen’s clinics are
located in Thailand, Cambodia, and Kyrgyzstan, and present a full
suite of services for its patients, including comprehensive
infertility and assisted reproductive technology treatments, egg
and sperm donation, and surrogacy, in the appropriate
jurisdictions, respectively. To learn more, visit
www.newgenivf.com. The information contained on, or accessible
through, NewGen’s website is not incorporated by reference into
this press release, and you should not consider it a part of this
press release.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally are identified by the words
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions. Without limiting the generality of the
foregoing, the forward-looking statements in this press release
include descriptions of the Company’s future commercial operations,
business strategy, and financial condition. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the Company’s annual
report on Form 20-F and other documents filed or to be filed by the
Company with the SEC from time to time, which could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Copies of these documents are available
on the SEC’s website, www.sec.gov. All information provided herein
is as of the date of this press release, and the Company undertakes
no obligation to update any forward-looking statement, except as
required under applicable law.
Investor Relations Contact
ICR, LLCRobin YangPhone: +1 (212)
537-4406Email: Newgenivf.IR@icrinc.com
NewGenIvf (NASDAQ:NIVF)
Historical Stock Chart
From Feb 2025 to Mar 2025
NewGenIvf (NASDAQ:NIVF)
Historical Stock Chart
From Mar 2024 to Mar 2025